CLINICAL AND IMMUNOLOGICAL PRESENTATION OF ATAXIA-TELANGIECTASIA

Oksana BOYARCHUK1, Larysa KOSTYUCHENKO2, Alla VOLOKHA3, Anastasia BONDARENKO3, Anna HILFANOVA3, Yaryna BOYKO2, Mariya KINASH1, Tetyana HARIYAN1, Yuriy STEPANOVSKYY3, Liubov VOLIANSKA1, Liudmyla CHERNYSHOVA3

1 Department of Children’s Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine
2 Pediatric Immunology and Rheumatology Clinic, Western-Ukrainian Specialized Children’s Medical Centre, Lviv, Ukraine
3 Department of Pediatric Infectious Diseases and Pediatric Immunology, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

ABSTRACT

Introduction. Ataxia-telangiectasia (A-T) is a neurodegenerative disorder characterised by progressive ataxia, telangiectasia, immunodeficiency, increased susceptibility to malignancies and radiation sensitivity.

The objective of the study was to determine the clinical and immunological features, as well as the consequences of A-T in the Ukrainian population.

Material and methods. Sixty-four patients with A-T, registered at the Ukrainian National Registry of primary immunodeficiencies, were first included in the study. The evaluation of clinical signs and investigations were possible in 53/64 patients with A-T.

Results. Neurological signs and telangiectasies were evidenced in all patients, and were followed by recurrent infections (81.1%), lymphoid hypoplasia (66.0%), and malignancies (15.1%). Poor weight gain was observed in 73.6% of patients, orthopaedic disorders in 52.8%, and bronchiectasis in 30.8%. High alpha-fetoprotein levels were seen in 93.5% of patients, mean level 150.3 IU/mL. Among immunoglobulin changes, high levels of IgA and IgM were observed in 85% and 75% of patients, respectively.

RéSUMÉ

Introduction. L’ataxie-télangiectasie (A-T) est une maladie neurodégénérative caractérisée par une ataxie progressive, une télangiectasie, une immunodéficience, une susceptibilité accrue aux tumeurs malignes et une sensibilité aux radiations.

Le but de l’étude était de déterminer les caractéristiques cliniques et immunologiques, ainsi que les conséquences de l’ataxie-télangiectasie (A-T) dans la population ukrainienne.

Matériel et méthodes. Soixante-quatre patients atteints d’A-T, enregistrés au Registre national ukrainien des déficits immunitaires primaires, ont été analysés. L’évaluation des signes cliniques et des investigations ont été possibles chez 53/64 patients atteints d’A-T.

Résultats. Des signes neurologiques et des télangiectasies ont été mis en évidence chez tous les patients et ont été suivis d’infections récurrentes (81.1%),
the most significant was a decreased IgA level (83.0%), followed by a high IgM level (50.9%), low IgG (18.9%) and IgE levels (49.1%). Reduced CD3, CD4 and CD8 T-lymphocytes were observed in 85.7% of patients. Infections and cancer were the most often causes of mortality. The mean age at death was 14.1 years, ranging from 6 to 21 years.

Conclusions. Ataxia in combination with recurrent infections is the key to AT diagnosis. In addition to syno-pulmonary infections, pyoderma and stomatitis are also frequent presentations. Children with ataxia should be referred to an immunologist, as well as genetic testing should be recommended for all patients with ataxia for timely diagnosis.

Keywords: ataxia-telangiectasia, clinical presentation, immunological features.

List of abbreviations:
- AFP – alpha-fetoprotein
- ATM – ataxia-telangiectasia mutated
- A-T – ataxia-telangiectasia
- CBC – complete blood count
- DNA – deoxyribonucleic acid
- ESID – European Society for Immunodeficiencies
- Ig – immunoglobulin
- IVIG – intravenous immunoglobulin
- JIA – juvenile idiopathic arthritis
- MRI – magnetic resonance imaging
- PID – primary immunodeficiency

INTRODUCTION

Ataxia-telangiectasia (A-T), also known as Louis-Bar’s syndrome, is an autosomal recessive neurodegenerative disorder characterized by progressive ataxia, telangiectasia, immunodeficiency, increased susceptibility to malignancies and radiation sensitivity. The disease is caused by a mutation of the Ataxia Telangiectasia Mutated (ATM) gene, encoding for the ATM protein. AT also refers to DNA damage response syndromes.

Ataxia is the main neurological manifestation of the disease, that is recognized when the baby starts walking or sitting. Progressive ataxia leads to disability and seriously reduces the quality of life in patients with A-T. The patients with ataxia are often monitored by neurologists due to different neurological diagnosis before other characteristic signs or manifestations of immunodeficiency occur.

A-T refers to a group of combined immunodeficiencies with associated or syndromic features. Immunodeficiency in patients with A-T is mostly manifested by sino-pulmonary infections and in more than 25% of A-T cases chronic lung disease develops.

One of the most serious manifestations of A-T is malignancy. About 25% of the A-T patients suffer from cancers. AT heterozygotes have also an increased risk of cancer, especially breast cancer (15%). Other manifestations of A-T include increased sensitivity to radiation, growth retardation, autoimmune disorders, endocrine disorders, early skin aging, cognitive impairments, and orthopaedic problems.

Knowledge about clinical and immunological features of A-T may help physicians with timely diagnosis and management of the disease.

The objective of the study was to determine the clinical and immunological presentation, and consequences of A-T in the Ukrainian population.

Materials and methods

64 patients (53 families) with A-T, registered in the Ukrainian National Registry of primary immunodeficiencies, were involved in this study. A-T cases...
have been diagnosed and registered in Ukraine since 1996. There were 5 families with two children and 3 families with three children with A-T. Six living patients have reached 18 years of age.

The diagnosis of A-T was based on clinical symptoms, genetic and biochemical tests according to the European Society for Immunodeficiencies (ESID) criteria for clinical diagnosis of A-T\(^1\). The registry data included the date and place of patient’s birth, age at the disease manifestation onset, age at diagnosis, patient’s status (alive or dead), cause of death, genetic diagnosis.

In addition, a questionnaire with detailed information about clinical signs (neurological findings, telangiectasia, infections, bronchiectasis, malignancies, allergies, and autoimmune disorders), complete blood count (CBC), alpha-fetoprotein (AFP) level, immunological examinations, neuroimaging, genetic diagnosis, treatment options of the patients with A-T was developed. Immunologists following-up the children with A-T were invited to fill in the questionnaires. The information about clinical signs and examinations results were provided for 53 patients affected by A-T.

Informed consent was obtained from all living adult participants in the study or from the parents of patients <18 years old. The experiment records were conducted following the guidelines of the Helsinki Declaration of 1975, as revised in 2000.

The statistical analysis was carried out using the statistical package STATISTICA 10.0 and table editor Microsoft Excel 2003. Continuous variables were expressed as means and SDs. The comparison of frequency parameters was performed using the \(\chi^2\) test. To determine the rank measure of association the Spearman’s correlation coefficient was calculated. Kaplan-Meier survival analysis was used to determine the survival probability of patients. The differences between the parameters were statistically significant at \(p<0.05\).

**Results**

**Demographic and clinical features**

According to the registry, from 64 patients with A-T, 33 are currently alive, 27 have died and 4 were lost to follow-up. The demographic features of the patients are presented in Table 1. There were two families where 2 children died and two families in which three children died because of A-T. There were no twins among the A-T patients; the parents did not report about any parental consanguinity, as well.

The mean onset age of the first A-T signs was 14.9 months, ranging from 3 months to 3 years. Commonly, A-T manifested with ataxia (56/87.5%). However, in some cases the first clinical manifestation was telangiectasia, which occurred in one patient at 3 months of age, or respiratory infections, pyelonephritis. The clinical manifestations of A-T patients are presented in Table 2. Ataxia occurred in all patients. The mean age of ataxia onset was 16.4, ranging from 6 months to 3 years. In 82.8% of patients, ataxia manifested before the age of 2 years. Commonly, the initial diagnosis in patients with A-T was cerebral palsy or ataxic syndrome. Less often myotonic syndrome, neurodegeneration with ataxia, or motor delay were registered. One child was misdiagnosed with Silver-Russell syndrome.

Dysarthria and oculomotor apraxia were less frequent, followed by loss of ability to walk and nystagmus. Most of the observed children (64.2%) required a wheelchair by the average age 7.9 years, range 6-12 years. Swallowing difficulties occurred in 13.2%, and intention tremor and myoclonic jerks in some cases.

Telangiectasies first appeared from 3 months to 12 years, the average age was 4.1 years. Ocular and skin telangiectasia occurred most often. Sometimes, ocular telangiectasia was misdiagnosed as allergic conjunctivitis. Almost a third of A-T patients presented with “café au lait” spots, vitiligo and follicular keratosis. Nevi, skin atrophy rarely occurred and seborrheic dermatitis was observed in one patient.

Lymphoid hypoplasia was observed as lymph nodes and tonsillar hypoplasia (66.0% and 64.2%, respectively). Evidence of thymic hypoplasia was present only in four patients; in other cases, these data were unclear.

Recurrent infections occurred in 81.1% of patients. Commonly bronchitis, pneumonia, pharyngitis/tonsillitis and sinusitis occurred (Table 2). Otitis, stomatitis, pyoderma and enterocolitis were observed less frequently. Warts, pyelonephritis, mycoses,

---

**Table 1. Demographic features of the A-T patients.**

| Characteristic features | Total (n=64) |
|------------------------|-------------|
| Age, mean ±SD, years; (range) | 14.8±7.1; (6 – 27) |
| Gender, male, n (%) / female, n (%); sex ratio | 34 (53.1%) / 30 (46.9%); 1.13 |
| Mean age at diagnosis, years; (range) | 6.2 (1 – 16) |
| Mean delay in diagnosis, years; (range) | 5.0 (0 – 13) |
| Living conditions, urban/ rural | 22/42 |
| Status: age, years | |
| Alive, n (%); mean age, (range) | 33 (51.6%); 14±5.8, (6 – 27) |
| Death, n (%); mean age, (range) | 27 (42.2%); 14±5.7, (6 – 21) |
| Lost to follow-up, n (%); mean age, (range) | 4 (6.2%); 22.5±12.2, (6 – 35) |
Herpes simplex infection and Molluscum contagiosum infection occurred in some cases.

Bronchiectasis was confirmed by computed tomography of the chest in 30.8% (12/39) of the examined patients with history of recurrent pulmonary infections. Interstitial lung disease was demonstrated in one patient.

Autoimmune diseases occurred rarely (7.5%), with thrombocytopenia in two cases and arthritis also in two cases. Allergies were observed in 17.0% of the patients and commonly manifested as eczema.

Malignancies occurred in 15.1%, most commonly lymphomas (6 cases): 5 non-Hodgkin’s and one Hodgkin’s lymphoma. Leukaemia occurred in one patient, and a single thyroid gland carcinoma. Leukaemia and lymphoma developed in all patients before 10 years of age.

A family history of cancer occurred in 9/53 (17.0%) patients with A-T, most commonly colon cancer (3 cases), lung cancer (3 cases), and leukaemia (2 cases). Other malignancies in close relatives included breast, prostate, bladder, throat, brain, skin cancers, and hepatocarcinoma.

Orthopaedic manifestations were present in 52.8% of the patients. Acquired foot deformity occurred most often, followed by scoliosis. Contractures, kyphosis, flat feet occurred in rare cases.

Poor weight gain was evident in 39/53 (73.6%) patients and growth delay in 20/53 (37.7%) patients. The mean weight for age z-score was –2.9±2.1, with the lowest value –6.3, and the mean height for age z-score was –1.9±1.4, with the lowest value –4.7.

Among other manifestations, gastric ulcer, liver angiomatosis, epileptic syndrome, congenital heart disease and coloboma were observed in rare cases.

Laboratory findings

Laboratory testing demonstrated anaemia in 10/53 (18.9%) patients, leukaopenia in 11/53 (20.8%) patients, with the lowest value 2.7×10^9/L. Lymphopenia was observed in 37/53 (69.8%) patients, with a mean value of (1.78±0.91)×10^9/L. The erythrocyte sedimentation rate (ESR) was increased in 23/53 (43.4%) patients, although the platelet count was consistently normal.

Alpha-fetoprotein (AFP) levels were raised in 93.5% (43/46) patients, with a mean value of 150.3 IU/mL, range 1.7-402.7 IU/mL. AFP levels were in the normal range in only 3 cases: at ages 2.5, 9 and 14 years, all currently alive, with only mild neurological and immunological changes. There was a significant positive correlation between the patient’s age and AFP level (r= 0.5654, p<0.05). There was no relation between AFP level and malignancy in patients with A-T.
Immunoglobulin changes occurred in 47 (88.7%) patients. Immunoglobulin levels in the cohort of patients affected by A-T are presented in Table 3.

The decreased IgG level was observed in 18.9% of patients; however, only in two patients its value was <1.0 g/L and 9/53 (17.0%) patients had raised levels of IgG. A low IgA was commoner than a low IgG level (in 83.0%, p=0.0054), with only one case with a raised level. Contrarily, IgM level was increased in 50.9% of patients. Immunoglobulin E level in 49.1% of patients was decreased and a high IgE appeared in only one patient.

Table 3. Immunoglobulin levels in patients with A-T (n=53).

| Immunoglobulin (Ig) | Deviation | n (%) | M±SD, range |
|---------------------|-----------|-------|-------------|
| Ig G, g/l           | decreased | 10 (18.9) | 8.51±4.16 (0.18 – 19.52) |
| Ig A, g/l           | decreased | 44 (83.0) | 0.30±0.35 (0 – 1.43) |
| Ig M, g/l           | increased | 27 (50.9) | 1.86±1.65 (0.41 – 8.76) |
| Ig E, IU/ml         | decreased | 26 (49.1) | 60.59±162.05 (0.1 – 700) |

Figure 1. The relationship of the mean levels of IgG (a), IgA and IgM (b) with age.
The dependence of the mean levels of IgG, IgM, and IgA on age in the patients with A-T is presented in Fig. 1. The figures show the increase of IgG and IgM levels with age; moreover, the mean levels of IgG were above the 2SD in patients over 13 years of age, whereas the mean levels of IgM were high in almost all ages. Fluctuations in the IgA levels were insignificant, with a tendency to decrease in patients over 14 years old. There was a positive significant correlation between the IgG level and age (r=0.52; p<0.05), and a negative correlation between IgG level and recurrent infections (r= -0.35; p<0.05) in patients with A-T.

Lymphocyte subpopulation profiles were available in 35 patients with A-T. Among them, lymphocyte subpopulation abnormalities were observed in 30 (85.7%) patients, although a significant decrease of CD3, CD4, CD8 and CD19 lymphocytes (<100 cells/mm³) was revealed only in one patient, in whom lymphoma developed. The deviation of proportion and number of lymphocyte subpopulation in patients with A-T is presented in Table 4.

More than half of the examined patients with AT presented reduced CD3, CD4 and CD8 T-lymphocytes. A decreased CD4 level was observed most often. The amount of NK lymphocytes was variable.

CT or MRI showed cerebellar atrophy or hypoplasia in 8 of 24 patients (33.3%) (Fig. 2). The mean age of revealing neuroimaging changes was 10.0±3.3 years old, ranging from 6 to 16 years. Vascular disorders were observed in two patients. Diffuse cerebral degenerative changes were also described in two patients.

**Treatment**

The main methods of treatment were immunoglobulin replacement therapy and prophylactic antibiotic therapy. Intravenous immunoglobulin replacement therapy was prescribed to 17 (32.1%) patients, especially those with a low Ig level and/or with recurrent pulmonary infections. The mean age of starting immunoglobulin therapy was 8.3 years, ranging from 2 to 17 years. Prophylactic antibiotic therapy was administered in 16 (30.2%) patients with respiratory symptoms. Amoxicillin, trimethoprim-sulfamethoxazole, and azithromycin were usually prescribed. Techniques for clearance of bronchial secretions were also used in some cases. Other treatment options included antioxidant drugs and symptomatic therapy.

**Outcomes**

The main causes of deaths were infections (12/27, 44.4%) and malignancies (7/27, 25.9%). In 8 (29.6%) patients, the causes were unknown. Lymphoma and leukaemia led to death in 6 and one case, respectively. Among infections, pneumonia contributed to death in 9 (33.3%) cases, sepsis in 2 cases, and systemic candidiasis in one case.

The Kaplan-Meier disease survival curve for patients with A-T is presented in Fig. 3.
median survival was 16 years. The twenty-year survival rate was estimated 35%.

DISCUSSION

The A-T cohort is one of the largest in the National registry among PIDs, therefore the evaluation of the clinical symptoms is very important for a timely diagnosis\[12\]-\[14\]. Ataxia and telangiectasia occurred in all observed patients. However, some researchers noticed that telangiectasia may be absent in some patients, even with a classic disease course\[1\]. Commonly, ataxia was the first symptom and appeared before the age of 2 years. Neuroimaging did not reveal cerebellar atrophy or hypoplasia in the first years of life, with MRI or CT changes appearing after the age 6 years. Other studies have also reported normal neuroimaging studies in the toddlers with A-T\[1,15\].

Recurrent infections were observed in 81.1% of the A-T patients, usually syno-pulmonary infections (bronchitis and pneumonia). Most studies also observed the predominance of syno-pulmonary infections, although some researchers indicated the prevalence of otitis (41%) in patients with A-T, whereas bronchitis and pneumonia occurred less often (in 19% and 15%, respectively)\[16\]. The data on other types of infections are very poor\[1,7,16\]. However, a quarter of our children with A-T suffered from pyoderma. Stomatitis, enterocolitis, pyelonephritis, mycoses, Herpes infection occurred less frequently. Warts, Molluscum contagiosum infection occurred very rarely, that is consistent with other studies\[16\]. Bronchiectasis was revealed in 30.8% of the patients with A-T. Other researchers reported similar data; chronic lung disease was diagnosed in more than 25% of the patients with A-T\[1\].

Allergy and autoimmune diseases were rarely reported in patients with A-T\[1,17\]. Allergies were observed in 17.0% of patients and autoimmunity in 7.5%. Juvenile idiopathic arthritis (JIA) was diagnosed in a 4-year-old male patient with A-T. To the best of our knowledge, the literature has reported only two cases of JIA in patients with A-T, one of them being from our cohort\[18,19\].

Malignancies occurred in 15.1% of the reported cohort and lymphoma was the most common. The incidence and prevalence of lymphoma are compared with other studies\[1,7,20,21\]. Colon and lung cancer were the most frequent among sibs, whereas breast, prostate and bladder cancers occurred more rarely.

Poor weight gain was more common and more significant than growth delay in the studied cohort, however, other studies reported that growth impairment was more prominent, and growth factor, hormone levels, as well as nutrition and infections contributed to this manifestation\[1,12\].

Among complete blood count testing, the most notable was lymphopenia, that occurred in 69.8% of patients with A-T, a distinguishing finding in patients with A-T\[1,7\], and the percentage is similar to that reported previously\[16\].

High AFP level is one of the main laboratory features of A-T. Overall, 93.5% of patients experienced increased AFP level. The mean AFP level (150.3 IU/mL) was consistent with other researches\[23\]. Our study has proved a positive correlation between the AFP level and age, which is also reported by some researchers\[24\].

The immunoglobulin pattern in patients with A-T showed most frequent changes of IgA, which was low in 83.0% of patients with A-T. The other significant sign was a high IgM level in 50.9% of the patients. The decrease of IgG and IgE levels occurred more rarely, in 18.9% and 49.1%, respectively. Similar changes are reported in other studies\[1,6,7,25\], however
some researchers detected a low level of IgG, IgA and IgE in 18%, 63%, 23%, respectively, of the patients with AT, that was slightly less than in our cohort. We also revealed an increase of IgG and IgM levels with age in patients with AT, whereas fluctuations in the IgA level were minor, with a tendency to decrease after 14 years. The researchers described a more severe course of the disease in cases of hyper IgM.

Lymphocyte subpopulation abnormalities were evidenced in 85.7% of the patients with AT. Most of the patients had reduced CD3, CD4 and CD8 T-lymphocytes. Most often, decreased CD4 levels were seen. There were no correlations between the numbers of T-cells and the frequency of infections. A low number of total and naïve CD4 T-lymphocytes was reported in other studies; other researchers outlined commonly decreased numbers of B-cells and CD4 cells. The low numbers of naïve T cells and normal terminal differentiation of antigenic stimulation of peripheral T cells was proved in patients with AT, therefore the patients with AT had no clinical signs of a T-cell deficiency. The number of NK lymphocytes in our cohort was variable; however, another study demonstrated normal levels of NK cells in patients with AT. Probably, the high levels of NK cells in some patients with AT may evidence an excessive activation of antitumour immunity, which needs to be studied.

Our study has shown that the main cause of mortality was infections (44.4%), followed by cancer (25.9%). Multivariate analyses of mortality factors in patients with AT prove the associations between morbidity, mortality, and ATM genotype. Biallelic mutations in ATM are associated with a high-risk of cancer (mainly hematologic malignancies) at young age, whereas hypo-morphic mutations in ATM have greater mortality from respiratory infections. The high number of recurrent respiratory infections in AT patients in this study was similar to others, as well as the high mortality rate from infections also indicates the need to determine the genetic pattern of AT in our population. The median survival in the Ukrainian population is low (16 years of age), and the twenty-year survival rate is 35%, whereas in the French population the twenty-year survival rate is higher (53.4%), however it has not changed since 1954. The early genetic diagnosis may impact treatment and preventive measures and help prolong the lives of patients and quality of their lives.

**CONCLUSIONS**

Ataxia in combination with recurrent infections is the key to AT diagnosis. In addition to syno-pulmonary infections, pyoderma and stomatitis are also frequent presentations. Infections and cancer are most often the causes of mortality in patients with AT.

Children with ataxia should be referred to an immunologist, as well as genetic testing should be recommended for all patients with ataxia, for a timely diagnosis. Increasing knowledge about clinical and immunological presentation of AT can also improve the early diagnosis, the management and prognosis of these patients.

**Authors’ contributions**

The study conception and design by O.B., L.K., A.V., A.B. Material preparation, data collection and analysis were performed by O.B., L.K., A.B., A.H., Y.B., M.K., T.H., Y.S. The first draft of the manuscript was written by O.B. and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript.

**Compliance with Ethics Requirements:**

“The authors declare no conflict of interest regarding this article”

“The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from the patients included in the study.”

“No funding for this study”

**Acknowledgments**

The authors would like to thank the immunologists Oksana Malko, Iryna Hrabovska, Lyubov Dmytrash, Tetyana Grishyna for their collaboration; patients and their families for the participation in this study.

**REFERENCES**

1. Rothblum-Ovitt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):159.
2. Schoenaker MHD, Blom M, de Vries MC, Weemaes CMR, van der Burg M, Willemens MAAP. Early diagnosis of ataxia telangiectasia in the neonatal phase: a parents’ perspective. Eur J Paediatr. 2020;179(2):251–256.
3. Nissenkorn A, Ben-Zeev B. Ataxia telangiectasia. Handb Clin Neurol. 2015;132:199–214.
4. Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser. 1985;19:1–63.
5. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.
6. Noordzij JG, Wulffraat NM, Haraldsson A, et al. Ataxia-telangiectasia patients presenting with hyper-IgM syndrome. Arch Dis Child. 2009;94(6):448–449.
7. Van Os NJH, Haaxma CA, van der Flier M, et al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. 2017;59(7):680–689.

8. Suárez F, Mahlau N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J Clin Oncol. 2015;33(2):202–208.

9. Jerrak KJ, Mancuso T, Eisen A. Ataxia-telangiectasia gene (ATM) mutation heterozygosity in breast cancer: a narrative review. Curr Oncol. 2018;25(2):e176–e180.

10. Nissenkorn A, Levy-Shraga Y, Banet-Levi Y, et al. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. 2016;79(6):889–894.

11. Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019;7(6):1763–1770.

12. Boyarchuk O, Balatska N, Chornomydz Y. Evaluation of warning signs of primary immunodeficiencies. Pediatr Polska – Polish Journal of Pediatrics. 2019;94(6):334–341.

13. Hariyan T, Kinash M, Kovalenko R, Boyarchuk O. Evaluation of awareness about primary immunodeficiencies among physicians before and after implementation of the educational program: A longitudinal study. PLoS ONE. 2020;15(5):e0233342.

14. Boyarchuk O, Dmytrash L. Clinical Manifestations in the Patients with Primary Immunodeficiencies: Data from One Regional Center. Turkish Journal of Immunology. 2019;7(3):113–119.

15. Hoche F, Seidel K, Theis M, et al. Neurodegeneration in ataxia telangiectasia: what is new? What is evident? Neuropediatrics. 2012;43(3):119–29.

16. Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, Carson KA, Lederman HM. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr. 2004;144:505–511.

17. Boyarchuk O. Allergic manifestations of primary immunodeficiency diseases and its treatment approaches. Asian Journal of Pharmaceutical and Clinical Research. 2018;11(11):83–90.

18. Pasini AM, Gagro A, Roic G, Vrdoljak O, Luic L, Zutelj M. Ataxia-Telangiectasia and Juvenile Idiopathic Arthritis. Pediatrics. 2017;139(2):e20161279.

19. Kinash M, Boyarchuk O, Shulhai O, Boyko Y, Hariyan T. Primary immunodeficiencies associated with DNA damage response: complexities of the diagnosis. Arch Balk Med Union. 2020;55(3):11–18.

20. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97:813–22.

21. Micol R, Slama LB, Suárez F, et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol. 2011;128(2):382–389.

22. Voss S, Pietzner J, Hoche F, et al. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors. 2014;32(3–4):123–9.

23. Moïn M, Aghamohammadi A, Kouhi A, et al. Ataxia-telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol. 2007;37(1):21–28.

24. Stray-Pedersen A, Borresen-Dale AL, Paus E, Lindman CR, Burgers T, Abrahamson TG. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol. 2007;11:375–380.

25. Driessen GJ, IJspeert H, Weemaes CM, et al. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin Immunol. 2013;131:1367–1375.

26. Boyarchuk O, Volokha A, Hariyan T, et al. The impact of combining educational program with the improving of infrastructure to diagnose on early detection of primary immunodeficiencies in children. Immunologic Research. 2019;63(4–5):390–397.

27. Maródi L; J Project Study Group. The Konya Declaration for Patients with Primary Immunodeficiencies. J Clin Immunol. 2020;10.1007/s10875-020-00797-4.